RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma

This study is a prospective, open-label, multicenter, real-world clinical study to evaluate the efficacy and safety of tunlametinib in patients with NRAS-mutant advanced melanoma who have failed prior anti-PD-1/PD-L1 therapy.

Trial Details

NCT ID
NCT07445022
Phase
PHASE4
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • tunlametinib
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Aged ≥18 years (inclusive), male or female;
  • Patients with histologically or cytologically confirmed locally advanced or metastatic melanoma;
  • Prior genetic testing results showing positive NRAS mutation;
  • Patients who have failed prior anti-PD-1/PD-L1 therapy;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →